StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Corporate ActionJun 15, 2026, 04:08 PM

Alvotech Terminates ATM Prospectus Supplement

AI Summary

Alvotech announced the termination of its prospectus supplement related to the potential issuance of ordinary shares through an At-The-Market (ATM) offering. Effective June 15, 2026, the company will suspend its use of this supplement, meaning no further sales of securities will occur under the existing Sales Agreement until a new prospectus supplement or registration statement is filed. The underlying Sales Agreement with Jefferies LLC, however, remains active.

Key Highlights

  • Alvotech terminated its ATM Prospectus Supplement on June 15, 2026.
  • The prospectus supplement was related to the potential issuance of ordinary shares.
  • No sales of securities will be made under the Sales Agreement without a new prospectus supplement or registration statement.
  • The Open Market Sale AgreementSM, dated June 14, 2024, remains in full force and effect.